PEPGEN INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
PEPGEN INC. (PEPG) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 505.55 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-06
- PEPGEN INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 286.08K shares, a 60.03% decline year-over-year.
- PEPGEN INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 219.47K shares, a 15.17% decline year-over-year.
- PEPGEN INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 379.45K shares, a 1766.54% increase year-over-year.
- PEPGEN INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 416.17K shares, a 503.23% increase year-over-year.
- PEPGEN INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 1.77M shares, a 400.84% increase from fiscal 2024.
- PEPGEN INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 353.42K shares, a 17.85% decline from fiscal 2023.
- PEPGEN INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 430.22K shares, a 2133.38% increase from fiscal 2022.
- PEPGEN INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 19.26K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 286.08K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 505.55K shares 10-Q · filed 2026-08-06 | 885.00K shares derived: sum of 3 quarters · filed 2026-08-06 | 1.30M shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 219.47K shares 10-Q · filed 2026-05-12 | 598.92K shares derived: sum of 2 quarters · filed 2026-05-12 | 1.02M shares derived: sum of 3 quarters · filed 2026-05-12 | 1.73M shares derived: sum of 4 quarters · filed 2026-05-12 |
| 2025-12-31 | 379.45K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | 795.61K shares derived: sum of 2 quarters · filed 2026-03-04 | 1.51M shares derived: sum of 3 quarters · filed 2026-03-04 | 1.77M shares 10-K · filed 2026-03-04 |
| 2025-09-30 | 416.17K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | 1.13M shares derived: sum of 2 quarters · filed 2025-11-12 | 1.39M shares 10-Q · filed 2025-11-12 | 1.41M shares derived: sum of 4 quarters · filed 2025-11-12 |
| 2025-06-30 | 715.69K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 974.43K shares 10-Q · filed 2025-08-07 | 994.76K shares derived: sum of 3 quarters · filed 2025-08-07 | 1.06M shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | 258.74K shares 10-Q · filed 2025-05-08 | 279.07K shares derived: sum of 2 quarters · filed 2025-05-08 | 348.06K shares derived: sum of 3 quarters · filed 2025-05-08 | 383.15K shares derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-12-31 | 20.33K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | 89.32K shares derived: sum of 2 quarters · filed 2025-02-24 | 124.42K shares derived: sum of 3 quarters · filed 2025-02-24 | 353.42K shares 10-K · filed 2025-02-24 |
| 2024-09-30 | 68.99K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 104.09K shares derived: sum of 2 quarters · filed 2024-11-07 | 333.09K shares 10-Q · filed 2024-11-07 | |
| 2024-06-30 | 35.10K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 264.10K shares 10-Q · filed 2024-08-08 | ||
| 2024-03-31 | 229.00K shares 10-Q · filed 2024-05-14 | |||
| 2023-12-31 | 430.22K shares 10-K/A · filed 2024-03-29 | |||
| 2022-12-31 | 19.26K shares 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |